Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover
Open Access
- 1 November 2011
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (11), 3367-3373
- https://doi.org/10.1210/jc.2011-0412
Abstract
Context: Determining how quickly bisphosphonate treatment effects begin to regress is crucial when considering termination of treatment. Objective: Our objective was to assess the effects of 1 yr discontinuation of risedronate use in postmenopausal women with osteoporosis who had previously received risedronate for 2 or 7 yr. Design and Setting: Before initiation of the current study, placebo/5-mg-risedronate patients had received placebo for 5 yr and risedronate for 2 yr, whereas 5-mg-risedronate patients had received risedronate for a total of 7 yr. Risedronate was then discontinued for 1 yr (yr 8). Patients: Postmenopausal women with osteoporosis who had previously completed the 3-yr Vertebral Efficacy with Risedronate Therapy MultiNational (VERT-MN) pivotal trial, plus a 2-yr extension comparing risedronate or placebo for a total of 5 yr, followed by 2 yr of open-label risedronate treatment were enrolled in these trial extensions. Main Outcome Measures: Evaluations included changes in type I collagen cross-linked N-telopeptide (NTX)/creatinine (Cr) and bone mineral density (BMD) values, fracture incidence, and adverse events. Results: After 1 yr of risedronate discontinuation, NTX/Cr levels increased toward baseline in both patient groups vs. the values at the end of yr 7. In both treatment groups, off-treatment total hip and femoral trochanter BMD values decreased, whereas lumbar spine and femoral neck BMD were maintained or slightly increased. The adverse event profiles were similar between the two treatment groups during yr 8. Conclusions: One year of discontinuation of risedronate treatment in patients who had received 2 or 7 yr of risedronate therapy led to increases in NTX/Cr levels toward baseline and decreases in femoral trochanter and total hip BMD.Keywords
This publication has 16 references indexed in Scilit:
- Prolonged antiresorptive activity of zoledronate: A randomized, controlled trialJournal of Bone and Mineral Research, 2010
- Re-initiation of risedronate 5 mg daily therapy in patients on long-term treatment after 1 year of discontinuation: effects at 9 and 10 yearsBone, 2010
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyOsteoporosis International, 2008
- Fracture risk remains reduced one year after discontinuation of risedronateOsteoporosis International, 2007
- Seven Years of Treatment with Risedronate in Women with Postmenopausal OsteoporosisCalcified Tissue International, 2004
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenThe New England Journal of Medicine, 2004
- Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experienceBone, 2003
- Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 2000
- Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post‐menopausal osteoporosisClinical Endocrinology, 1997